We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Xavier Montalban (St Michael’s Hospital, University of Toronto, Toronto, Canada and Vall d’Hebron University Hospital, Barcelona, Spain) shares his expert insights on the rationale for the use of evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in the treatment of patients with relapsing multiple sclerosis (MS), as well as an overview of key efficacy and safety […]
Great to have an opportunity to speak with Celia Oreja-Guevara (University Hospital San Carlos and University Complutense, Madrid, Spain) around the highlights of her presentation entitled: Regional outcomes of eculizumab treatment in patients with aquaporin-4 immunoglobin G-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study (ClinicalTrials.gov Identifier: NCT01892345). Questions 1. What were […]
Bianca Weinstock-Guttman (Jacobs School of Medicine and Biomedical Science, University of Buffalo, NY, USA) shares highlights of her presentation entitled: Effectiveness and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior disease-modifying therapy: 2-year findings from CHORDS (ClinicalTrials.gov Identifier: NCT02637856). Questions 1. What are the potential advantages of […]
Great to catch-up with Andrew Chan (Inselspital Bern, University Hospital, University of Bern, Bern, Switzerland), who discussed challenges posed to patient care by COVID-19, factors to consider around immunosuppression for patients with multiple sclerosis (MS) during the pandemic, as well his personal thoughts on exciting developments in MS therapy and the 1st Virtual EAN Congress. […]
Anna Tancin Lambert (University of Oslo and Department of Neurology Østfold Hospital Trust, Norway) discussed with us exciting interim findings from the international, multicentre, prospective, observational Nordic Atrial Fibrillation and Stroke (NOR-FIB) study, which highlight atrial fibrillation as the hidden cause of cryptogenic stroke (ClinicalTrials.gov Identifier: NCT02937077). Questions 1. What proportion of stroke and transient […]
We caught up with our Editorial Board member, Angelo Antonini (University of Padova, Veneto, Italy), to discuss the neurological and psychiatric events that have been observed in patients with COVID-19, what could be done to prepare for these and if anything can be learnt from current experience. Questions 1. Could you tell us about the […]
Uwe Reuter (Charité Universitätsmedizin Berlin, Germany) talks to us about the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine (ClinicalTrials.gov Identifier: NCT03828539). Questions 1. What are the unmet needs in the treatment of episodic migraine? (0:05) 2. Could you tell us a little about the […]
So pleased to have had an opportunity to catch-up with editorial board member, K Ray Chaudhuri (King’s Parkinson’s Centre, King’s College Hospital and Kings College London, UK), who shared his expert perspective on the clinical impact of COVID-19 on people with Parkinson’s disease. Questions 1. What treatment strategies should be implemented in patients with Parkinson’s […]
So pleased to have had an opportunity to catch-up with editorial board member, K Ray Chaudhuri (King’s Parkinson’s Centre, King’s College Hospital and Kings College London, UK), who shared his expert perspective on the clinical impact of COVID-19 on people with Parkinson’s disease. Question What is the clinical impact of COVID-19 on people with Parkinson’s […]
Get the latest clinical insights from touchNEUROLOGY